Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung‐Jue BangSeoul National University College of Medicine, Seoul, South Korea. [email protected]Eric Van CutsemUniversity Hospital Gasthuisberg, Leuven, BelgiumA. FeyereislovaF Hoffmann-La Roche, Basel, SwitzerlandHyun Cheol ChungYonsei Cancer Center, Cancer Metastasis Research Center, Yonsei University College of Medicine, Seoul, South KoreaLin ShenPeking University, Beijing Cancer Hospital, Beijing, ChinaAkira SawakiAichi Cancer Center, Aichi, JapanFlorian LordickNationales Centrum für Tumorerkrankungen, Heidelberg, GermanyAtsushi OhtsuNational Cancer Center, Hospital East, Kashiwa, JapanYasushi OmuroTokyo Metropolitan Cancer and Infectious Diseases Center, Komagome General Hospital, Tokyo, JapanTaroh SatohKinki University School of Medicine, Osaka, JapanGiuseppe AprileЕ. С. КуликовRegional Clinical Oncology Dispensary, Ryazan, RussiaJulie HillRoche Products, Dee Why, NSW, AustraliaMichaela LehleF Hoffmann-La Roche, Basel, SwitzerlandJosef RüschoffYoon‐Koo KangAsan Medical Centre, Seoul, South Korea
2010en
ABI
Аннотация
Аннотация отсутствует.
Идентификаторы
Цитирования и источники
Цитирований: 3Использованных источников: 0